Cardiovascular Systems, Inc.
2715 Nevada Avenue North
New Hope
Minnesota
55427
United States
Tel: 763-544-1890
207 articles with Cardiovascular Systems, Inc.
-
Cardiovascular Systems, Inc. Reports Fiscal 2019 Second-Quarter Financial Results
1/30/2019
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its fiscal second quarter, ended December 31, 2018.
-
First Patients in the Middle East Treated with Cardiovascular Systems, Inc. Diamondback 360® Coronary Orbital Atherectomy System
1/16/2019
Introduction of Orbital Atherectomy in the Middle East by OrbusNeich® Expands Treatment Options for Patients with Complex Coronary Artery Disease
-
Cardiovascular Systems, Inc. Announces Preliminary Fiscal 2019 Second-Quarter Revenues of $60.2 Million
1/7/2019
Company Narrows Fiscal 2019 Revenue Guidance to a Range of $243 million to $247 million
-
Cardiovascular Systems, Inc. Receives Approval for the Diamondback 360® Coronary Orbital Atherectomy System with Classic Crown and New ViperWire Advance® FlexTip Guidewire in Japan
1/2/2019
Dr. Shigeru Saito Treats First Patient at Shonan Kamakura General Hospital
-
First Patients in Europe Treated with Cardiovascular Systems, Inc. Peripheral Orbital Atherectomy System
11/13/2018
Cardiovascular Systems, Inc. announced today that the first patients in Germany have been treated with its Stealth 360® Peripheral Orbital Atherectomy System (OAS).
-
First Patient in Hong Kong Treated with Cardiovascular Systems, Inc. Coronary Orbital Atherectomy System
11/8/2018
This procedure marks the first international coronary procedure taking place as a result of the company’s distribution agreement with OrbusNeich®.
-
Cardiovascular Systems, Inc. Reports Fiscal 2019 First-Quarter Financial Results
10/30/2018
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial results for its fiscal first quarter, ended September 30, 2018.
-
Cardiovascular Systems, Inc. to Webcast Fiscal 2019 First-Quarter Earnings Conference Call Tuesday, October 30
10/9/2018
Live Webcast at 3:45 p.m. CT (4:45 p.m. ET)
-
Cardiovascular Systems, Inc. Announces First Commercial Launch of Peripheral Orbital Atherectomy System Outside the United States
9/19/2018
Cardiovascular Systems, Inc.. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient in Hong Kong has been treated with its Stealth 360® Peripheral Orbital Atherectomy System (OAS).
-
Cardiovascular Systems Presents Liberty 360° Two-Year Outcomes at 2018 Amputation Prevention Symposium
8/8/2018
Late-breaking presentation shows high freedom from major amputation
-
Cardiovascular Systems, Inc. and Aerolase Corp. Sign Collaborative Agreement for Laser Atherectomy Technology
7/31/2018
Cardiovascular Systems, Inc. today announced that it has signed an agreement with Aerolase Corp. to co-develop a new laser atherectomy device for physicians to use in more effectively treating multiple forms of arterial disease.
-
Cardiovascular Systems, Inc. Reports Fiscal 2018 Fourth-Quarter Financial Results
7/30/2018
Webcast of analyst day on Tuesday, July 31 will begin at 9:00 AM ET with discussion of fiscal fourth-quarter results
-
Cardiovascular Systems, Inc. Signs International Distribution Agreement with OrbusNeich
7/16/2018
Cardiovascular Systems, Inc. has signed an exclusive international distribution agreement with OrbusNeich to sell its coronary and peripheral Orbital Atherectomy Systems (OAS) outside the United States and Japan.
-
Cardiovascular Systems, Inc. to Release Fiscal 2018 Fourth-Quarter Results on July 30
7/10/2018
Webcast of analyst day on July 31 will include discussion of fiscal fourth-quarter results.
-
Cardiovascular Systems, Inc. Reports Fiscal 2018 Third-Quarter Financial Results
5/2/2018
Cardiovascular Systems, Inc. reported financial results for its fiscal third quarter, ended March 31, 2018.
-
Sarepta Therapeutics is breathing a little easier this morning. On Wednesday a federal appeals court supported a previous court’s decision to dismiss charges that the company misled shareholders as it vied to gain approval for its Duchenne muscular dystrophy treatment.
-
Cardiovascular Systems, Inc. and OrbusNeich Announce FDA Clearance of the First and Only 1.0mm Coronary Balloon in the U.S.
3/1/2018
Device is the smallest, 510(k) cleared coronary balloon in the U.S. market
-
Life science companies are popular targets for securities fraud litigation.
-
Cardiovascular Systems, Inc. Announces First Patients Treated from Radial Access Using Its Diamondback 360 Extended Length Peripheral Orbital Atherectomy Device
2/14/2018
Cardiovascular Systems announced today that the first patients were treated using its FDA-cleared extended length Diamondback 360 Peripheral Orbital Atherectomy Device (OAD) to treat peripheral artery disease (PAD).
-
Cardiovascular Systems, Inc. Reports Fiscal 2018 Second-Quarter Financial Results
2/8/2018
The company’s second-quarter revenues were $52.6 million, an increase of $2.6 million from the second quarter of fiscal 2017.